PRF Technologies (PRFX) Operating Income (2020 - 2024)
PRF Technologies (PRFX) posted Operating Income of -$7.3 million for Q2 2024, down 31.99% on a QoQ basis from -$5.6 million in Q1 2024, and down 226.15% year-over-year from $5.8 million in Q3 2023.
PRF Technologies (PRFX) Operating Income (2020 - 2024) Analysis & Trends
PRF Technologies' Operating Income history runs 5 years deep, the most recent figure standing at -$7.3 million for Q2 2024.
- Quarterly Operating Income fell 226.15% year-over-year to -$7.3 million in Q2 2024, while the trailing twelve-month figure through Jun 2024 was -$17.8 million (down 77.9% YoY) and the FY2025 annual result came in at -$5.1 million, up 65.09% from the prior year.
- Operating Income was -$7.3 million for Q2 2024 at PRF Technologies, down from -$5.6 million in the prior quarter.
- Across five years, Operating Income topped out at -$132000.0 in Q1 2020 and bottomed at -$7.3 million in Q2 2024.
- A 5-year average of -$2.2 million and a median of -$1.8 million in 2021 frame the typical range for Operating Income.
- Annual changes were most pronounced in 2021 — Operating Income sank 1444.7% — and 2023, when it surged 35.5%.
- PRF Technologies' Operating Income stood at -$691000.0 in 2020, then slumped by 151.95% to -$1.7 million in 2021, then plunged by 87.02% to -$3.3 million in 2022, then dropped by 9.46% to -$3.6 million in 2023, then tumbled by 106.09% to -$7.3 million in 2024.
- Business Quant data shows PRFX's Operating Income at -$7.3 million in Q2 2024, -$5.6 million in Q1 2024, and -$3.6 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 652.00 Mn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 833.00 Mn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | -2.65 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 325.80 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | -79.70 Mn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 193.40 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 291.00 Mn |
| 10 | PRF Technologies | 714,066.24 | -326,933.76 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | -7.35 Mn |
| Mar 31, 2024 | -5.57 Mn |
| Dec 31, 2023 | -3.56 Mn |
| Sep 30, 2023 | -1.35 Mn |
| Jun 30, 2023 | -2.25 Mn |
| Mar 31, 2023 | -2.42 Mn |
| Dec 31, 2022 | -3.26 Mn |
| Sep 30, 2022 | -2.10 Mn |
| Jun 30, 2022 | -1.85 Mn |
| Mar 31, 2022 | -1.67 Mn |
| Dec 31, 2021 | -1.74 Mn |
| Sep 30, 2021 | -1.77 Mn |
| Jun 30, 2021 | -1.66 Mn |
| Mar 31, 2021 | -2.04 Mn |
| Dec 31, 2020 | -691,000.00 |
| Sep 30, 2020 | -700,000.00 |
| Jun 30, 2020 | -148,000.00 |
| Mar 31, 2020 | -132,000.00 |